BACKGROUND: Dilated cardiomyopathy (DCM) is a leading cause of heart failure and death. The etiology of DCM is genetically heterogeneous. OBJECTIVES: We sought to define the prevalence of mutations in the RNA splicing protein RBM20 in a large cohort with DCM and to determine whether genetic variation in RBM20 is associated with clinical outcomes. METHODS: Subjects included in the Genetic Risk Assessment of Defibrillator Events (GRADE) study were aged at least 18 years, had an ejection fraction of ≤30%, and an implantable cardioverter-defibrillator (ICD). The coding region and splice junctions of RBM20 were screened in subjects with DCM; 2 common polymorphisms in RBM20, rs942077 and rs35141404, were genotyped in all GRADE subjects. RESULTS: A total of 1465 subjects were enrolled in the GRADE study, and 283 with DCM were screened for RBM20 mutations. The mean age of subjects with DCM was 58 ± 13 years, 64% were males, and the mean follow-up time was 24.2 ± 17.1 months after ICD placement. RBM20 mutations were identified in 8 subjects with DCM (2.8%). Mutation carriers had a similar survival, transplantation rate, and frequency of ICD therapy compared with nonmutation carriers. Three of 8 subjects with RBM20 mutations (37.5%) had atrial fibrillation (AF), whereas 19 subjects without mutations (7.4%) had AF (P = .02). Among all GRADE subjects, rs35141404 was associated with AF (minor allele odds ratio = 0.62; 95% confidence interval = 0.44-0.86; P = .006). In the subset of GRADE subjects with DCM, rs35141404 was associated with AF (minor allele odds ratio = 0.58; P = .047). CONCLUSIONS: Mutations in RBM20 were observed in approximately 3% of subjects with DCM. There were no differences in survival, transplantation rate, and frequency of ICD therapy in mutation carriers. Copyright Â
BACKGROUND:Dilated cardiomyopathy (DCM) is a leading cause of heart failure and death. The etiology of DCM is genetically heterogeneous. OBJECTIVES: We sought to define the prevalence of mutations in the RNA splicing protein RBM20 in a large cohort with DCM and to determine whether genetic variation in RBM20 is associated with clinical outcomes. METHODS: Subjects included in the Genetic Risk Assessment of Defibrillator Events (GRADE) study were aged at least 18 years, had an ejection fraction of ≤30%, and an implantable cardioverter-defibrillator (ICD). The coding region and splice junctions of RBM20 were screened in subjects with DCM; 2 common polymorphisms in RBM20, rs942077 and rs35141404, were genotyped in all GRADE subjects. RESULTS: A total of 1465 subjects were enrolled in the GRADE study, and 283 with DCM were screened for RBM20 mutations. The mean age of subjects with DCM was 58 ± 13 years, 64% were males, and the mean follow-up time was 24.2 ± 17.1 months after ICD placement. RBM20 mutations were identified in 8 subjects with DCM (2.8%). Mutation carriers had a similar survival, transplantation rate, and frequency of ICD therapy compared with nonmutation carriers. Three of 8 subjects with RBM20 mutations (37.5%) had atrial fibrillation (AF), whereas 19 subjects without mutations (7.4%) had AF (P = .02). Among all GRADE subjects, rs35141404 was associated with AF (minor allele odds ratio = 0.62; 95% confidence interval = 0.44-0.86; P = .006). In the subset of GRADE subjects with DCM, rs35141404 was associated with AF (minor allele odds ratio = 0.58; P = .047). CONCLUSIONS: Mutations in RBM20 were observed in approximately 3% of subjects with DCM. There were no differences in survival, transplantation rate, and frequency of ICD therapy in mutation carriers. Copyright Â
Authors: Patrick T Ellinor; Sabine Sasse-Klaassen; Susanne Probst; Brenda Gerull; Jordan T Shin; Andrea Toeppel; Arnd Heuser; Beate Michely; Danita M Yoerger; Bong-Seok Song; Bernhard Pilz; Gregor Krings; Bruce Coplin; Peter E Lange; G William Dec; Hans Christian Hennies; Ludwig Thierfelder; Calum A MacRae Journal: J Am Coll Cardiol Date: 2006-06-21 Impact factor: 24.094
Authors: V V Michels; P P Moll; F A Miller; A J Tajik; J S Chu; D J Driscoll; J C Burnett; R J Rodeheffer; J H Chesebro; H D Tazelaar Journal: N Engl J Med Date: 1992-01-09 Impact factor: 91.245
Authors: Duanxiang Li; Sharie B Parks; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Susan Ludwigsen; Julie Partain; Randal R Nixon; Charles N Allen; Robert P Irwin; Petra M Jakobs; Michael Litt; Ray E Hershberger Journal: Am J Hum Genet Date: 2006-10-24 Impact factor: 11.025
Authors: Matthew R G Taylor; Dobromir Slavov; Andreas Gajewski; Sylvia Vlcek; Lisa Ku; Pamela R Fain; Elisa Carniel; Andrea Di Lenarda; Gianfranco Sinagra; Mark M Boucek; Jean Cavanaugh; Sharon L Graw; Patsy Ruegg; Jennie Feiger; Xiao Zhu; Debra A Ferguson; Michael R Bristow; Josef Gotzmann; Roland Foisner; Luisa Mestroni Journal: Hum Mutat Date: 2005-12 Impact factor: 4.878
Authors: Heather L Bloom; Irfan Shukrullah; Emir Veledar; Rebecca Gutmann; Barry London; Samuel C Dudley Journal: Cardiol Res Pract Date: 2010-03-25 Impact factor: 1.866
Authors: Sharie B Parks; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Susan Ludwigsen; Amanda Peterson; Duanxiang Li; Petra Jakobs; Michael Litt; Charles B Porter; Peter S Rahko; Ray E Hershberger Journal: Am Heart J Date: 2008-03-12 Impact factor: 4.749
Authors: Wael A AlJaroudi; Marwan M Refaat; Robert H Habib; Laila Al-Shaar; Madhurmeet Singh; Rebecca Gutmann; Heather L Bloom; Samuel C Dudley; Patrick T Ellinor; Samir F Saba; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Indrani Halder; Barry London Journal: Am J Cardiol Date: 2015-01-15 Impact factor: 2.778
Authors: Yiyi Zhang; Elena Blasco-Colmenares; Amy C Harms; Barry London; Indrani Halder; Madhurmeet Singh; Samuel C Dudley; Rebecca Gutmann; Eliseo Guallar; Thomas Hankemeier; Gordon F Tomaselli; Alan Cheng Journal: Europace Date: 2015-10-25 Impact factor: 5.214